We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+100.78%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$48.5M
Cap. Flow
-$50.1M
Cap. Flow %
-11.99%
Top 10 Hldgs %
89.13%
Holding
25
New
9
Increased
–
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
ALT icon
Altimmune
ALT
+$24.7M
2
KROS icon
Keros Therapeutics
KROS
+$20.7M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$14M
4
MYOV
Myovant Sciences Ltd.
MYOV
+$11.5M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$11.2M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$47.7M
2
INO icon
Inovio Pharmaceuticals
INO
+$21.6M
3
TXG icon
10x Genomics
TXG
+$18.7M
4
ETNB
89bio
ETNB
+$16.1M
5
MRSN
Mersana Therapeutics
MRSN
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 83.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
1
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$121M 28.9%
4,016,873
– –
TRIL
2
DELISTED
Trillium Therapeutics Inc.
TRIL
$54.9M 13.15%
6,790,000
– –
ALT icon
3
Altimmune
ALT
$552M
$48.2M 11.54%
+4,500,000
New +$24.7M
RLMD icon
4
Relmada Therapeutics
RLMD
$557M
$29.9M 7.16%
668,440
-174,374
-21% -$7.37M
SURF
5
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$25.4M 6.09%
+3,877,895
New +$14M
KROS icon
6
Keros Therapeutics
KROS
$199M
$25.2M 6.04%
+672,306
New +$20.7M
VXRT
7
DELISTED
Vaxart
VXRT
$24.5M 5.86%
+2,765,000
New +$7.94M
MYOV
8
DELISTED
Myovant Sciences Ltd.
MYOV
$17.4M 4.17%
+845,000
New +$11.5M
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$14.5M 3.48%
1,431,635
-194,075
-12% -$1.79M
NARI
10
DELISTED
Inari Medical, Inc. Common Stock
NARI
$11.4M 2.73%
+235,000
New +$11.2M
KURA icon
11
Kura Oncology
KURA
$800M
$9.37M 2.24%
+575,000
New +$8.29M
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.69B
$9.27M 2.22%
+625,710
New +$9.53M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$8.55M 2.05%
1,057,827
– –
ADAP
14
DELISTED
Adaptimmune Therapeutics
ADAP
$7.83M 1.87%
+781,940
New +$4.91M
ETNB
15
DELISTED
89bio
ETNB
$5.8M 1.39%
291,140
-661,060
-69% -$16.1M
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.58M 1.1%
378,888
-112,129
-23% -$1.39M
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
– –
-99,438
Closed -$9.71M
AXSM icon
18
Axsome Therapeutics
AXSM
$11.2B
– –
-810,000
Closed -$47.7M
INO icon
19
Inovio Pharmaceuticals
INO
$55.7M
– –
-241,667
Closed -$21.6M
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
– –
-104,956
Closed -$15.3M
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.79B
– –
-113,140
Closed -$799K
SPRO icon
22
Spero Therapeutics
SPRO
$67.7M
– –
-474,015
Closed -$3.83M
TXG icon
23
10x Genomics
TXG
$6B
– –
-300,000
Closed -$18.7M
VSTM icon
24
Verastem
VSTM
$510M
– –
-310,078
Closed -$9.82M
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,586,537
Closed -$8.9M

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q2 2020 Portfolio in Review

As of Q2 2020, VR Adviser held 25 positions worth $418M, up 13% from $369M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

VR Adviser withdrew a net $50.1M in Q2 2020, closing 9 positions and reducing 4 holdings. Its most notable exit was Axsome Therapeutics, an estimated $47.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier.

Against the trend, VR Adviser opened a new position in Altimmune worth $48.2M.

  • VR Adviser's largest Q2 2020 buy was Altimmune: 4,500,000 shares worth $48.2M.
  • VR Adviser's biggest Q2 2020 reduction was 89bio, cutting an estimated $16.1M.
  • VR Adviser fully exited Axsome Therapeutics in Q2 2020, selling an estimated $47.7M.
  • VR Adviser's ten largest holdings make up 89% of its $418M portfolio in Q2 2020.
  • VR Adviser opened 9 new positions and closed 9 in Q2 2020.
  • VR Adviser's portfolio value rose 13% quarter-over-quarter to $418M.

Based on VR Adviser's 13F filing for Q2 2020, filed 14 Aug 2020.